Sach, Tracey ORCID: https://orcid.org/0000-0002-8098-9220
(2018)
Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid.
British Journal of Dermatology, 178 (2).
pp. 320-321.
ISSN 0007-0963
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cost-benefit analysis,doxycycline,humans,pemphigoid, bullous,prednisolone,quality-adjusted life years |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
Depositing User: | LivePure Connector |
Date Deposited: | 16 Jul 2020 23:47 |
Last Modified: | 22 Oct 2022 06:30 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/76154 |
DOI: | 10.1111/bjd.16226 |
Actions (login required)
![]() |
View Item |